---
schema_version: "secwatch.filing_event.v1"
accession: "0001093557-24-000197"
form_type: "8-K"
ticker: "DXCM"
cik: "0001093557"
company_name: "DEXCOM INC"
filed_at: "2024-12-23T23:59:59+00:00"
generated_at: "2026-05-28T23:29:52.392285+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# DexCom and Abbott settle global patent litigation, enter royalty-free cross-license

## Summary
- DexCom and Abbott signed a settlement and patent cross-license agreement on Dec 20, 2024.
- Each party grants the other a worldwide, royalty-free, non-exclusive license to certain analyte-sensing patents.
- No royalties or any financial compensation are required under the agreement.
- Both parties entered a covenant not to sue until December 20, 2034.
- Non-challenge provisions apply to licensed patents for varying periods.

## SEC filing metadata
- accession: 0001093557-24-000197
- form_type: 8-K
- ticker: DXCM
- cik: 0001093557
- company_name: DEXCOM INC
- filed_at: 2024-12-23T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000197/0001093557-24-000197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000197/dxcm-20241220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001093557-24-000197
- JSON: https://secwatch.observer/filing/0001093557-24-000197.json
- Plain text: https://secwatch.observer/filing/0001093557-24-000197.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.